BRIEF FDA Grants Priority Review For Lilly\'s Verzenio

Oct 12 (Reuters) - Eli Lilly And Co:

* FDA grants priority review for potential new indication for Lilly’s verzenio (abemaciclib) as initial treatment of advanced breast cancer

* Eli Lilly And Co - ‍FDA’s goal is to take action within eight months of receiving an application, compared with standard review timeframe of 12 months​ Source text for Eikon: Further company coverage:

Source : https://cn.reuters.com/article/brief-fda-grants-priority-review-for-lil-idCNASB0BMTW

BRIEF-FDA grants priority review for Lilly's verzenio
FDA grants priority review for Lilly's Verzenio as initial treatment of advanced breast cancer
FDA Grants Priority Review for Potential New Indication for Lill - KAIT Jonesboro, AR - Region 8 News, weather, sports
Lilly's Verzenio Gets FDA Priority Review Designation For Advanced Breast Cancer
FDA Nod For Breast Cancer Combo Therapy, RARE Scripts History, EDAP Disappoints
BRIEF-FDA grants priority review for Lilly's verzenio
FDA Grants Priority Review for Potential New Indication for Lilly's Verzenio™ (abemaciclib) as Initial Treatment of Advanced Breast Cancer
BRIEF-FDA grants priority review for Lilly's abemaciclib
BRIEF-FDA grants priority review for Lilly's Olaratumab
[LIMITED STOCK!] Related eBay Products